JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Kodu・Aktsiate loetelu・Kymera Therapeutics Inc

Kymera Therapeutics Inc

Avatud

SektorTervishoid

80.6 -0.59

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

80.28

Max

81.54

Põhinäitajad
By Trading Economics
Sissetulek	-4.8M -87M
Müük	96K 2.9M
Kasumimarginaal	-3,041.294
Töötajad	238
EBITDA	-5.8M -85M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+43.65% upside

Turustatistika
By TradingEconomics
Turukapital	2.4M 7.1B
Eelmine avamishind	81.19
Eelmine sulgemishind	80.6

Uudiste sentiment

By Acuity

38%

62%

137 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

28.34 / 33.56 Toetus ja vastupanu

Kymera Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. dets 2025, 08:30 UTC

Omandamised, ülevõtmised, äriostud

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Kymera Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

43.65% tõus

12 kuu keskmine prognoos

Keskmine 120.08 USD 43.65%

Kõrge 140 USD

Madal 100 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Kymera Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

Osta

Hoia

Müü

Põhineb 15 analüütiku instrumendi Kymera Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

28.34 / 33.56Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

137 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.